Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Nektar Therapeutics - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
NKTR
Nasdaq
2834
www.nektar.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Nektar Therapeutics
Zacks Industry Outlook Highlights Corcept, Amneal, Dyne, Nektar and Cardiol
- Feb 3rd, 2025 9:09 am
Nektar (NKTR) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
- Jan 31st, 2025 2:55 pm
5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era
- Jan 31st, 2025 1:03 pm
MediWound (MDWD) Surges 8.5%: Is This an Indication of Further Gains?
- Jan 27th, 2025 11:32 am
Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AD Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Moderate-to-Severe Atopic Dermatitis
- Jan 10th, 2025 12:00 pm
Why Nektar Therapeutics (NKTR) Is Among the Best Penny Stocks to Invest In According to Media?
- Jan 7th, 2025 2:24 pm
Institutional investors have a lot riding on Nektar Therapeutics (NASDAQ:NKTR) with 68% ownership
- Jan 4th, 2025 12:48 pm
Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting
- Dec 7th, 2024 5:00 pm
Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence
- Nov 18th, 2024 8:30 pm
Nektar Therapeutics (NASDAQ:NKTR) Just Reported And Analysts Have Been Lifting Their Price Targets
- Nov 10th, 2024 2:43 pm
Nektar Therapeutics Third Quarter 2024 Earnings: Beats Expectations
- Nov 9th, 2024 12:04 pm
Nektar Q3 Loss Narrower Than Expected, Pipeline Development in Focus
- Nov 8th, 2024 5:02 pm
Nektar Therapeutics (NKTR) Q3 2024 Earnings Call Highlights: Strategic Moves and Financial Outlook
- Nov 8th, 2024 7:30 am
Nektar Therapeutics (NKTR) Reports Q3 Loss, Tops Revenue Estimates
- Nov 7th, 2024 10:40 pm
Nektar: Q3 Earnings Snapshot
- Nov 7th, 2024 9:36 pm
Nektar Therapeutics Reports Third Quarter 2024 Financial Results
- Nov 7th, 2024 9:15 pm
Nektar and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia in Locally Advanced Non-Small Cell Lung Cancer Patients at Society for Immunotherapy of Cancer (SITC) Annual Meeting
- Nov 7th, 2024 3:15 pm
Nektar Therapeutics to Participate in Upcoming Investor Conferences
- Nov 6th, 2024 11:00 pm
Nektar Therapeutics to sell Alabama facility to Ampersand
- Nov 5th, 2024 3:34 pm
Eczema Drug Developer Nektar Gains Analyst Confidence With 400% Upside Potential
- Nov 4th, 2024 6:44 pm
Scroll